NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

https://clincancerres.aacrjournals.org/content/27/1/11

CCR Perspectives in Regulatory Science and Policy

U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program

R. Angelo de Claro, Jennifer J. Gao, Tamy Kim, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver and Richard Pazdur
Add to Cart ($50)

DOI: 10.1158/1078-0432.CCR-20-2220 Published January 2021

Abstract

The FDA Oncology Center of Excellence commenced the Real-Time Oncology Review (RTOR) pilot project in February 2018 to facilitate earlier submission of topline results and datasets to support an earlier start to the FDA application review. RTOR was initially begun to support supplemental drug applications to add new indications, dosing regimens, or other clinical information to the prescribing information, but was later expanded to include original new drug applications and biological license applications for new molecular entities (NME). From February 2018 to April 2020, RTOR was used to support the submission and review of drug approvals for 20 oncology applications (11 for solid tumor and nine for hematologic malignancy indications). Two were NME drug approvals and 18 were supplemental approvals. All of the applications received priority review and nine (45%) applications had received breakthrough therapy designation status. FDA received the RTOR submissions a median of 5.7 weeks (range 1.7–16.2 weeks) prior to the full application submission. The median time from application submission to FDA approval was 3.3 months (range 0.4–5.9 months). RTOR was also integrated with other review programs including the Assessment Aid and Project Orbis programs. Innovative regulatory processes are critical to expedite the rigorous review of impactful products across the FDA.

Footnotes

Clin Cancer Res 2021;27:11–4

Received June 9, 2020.
Revision received July 20, 2020.
Accepted August 17, 2020.
Published first August 19, 2020.

©2020 American Association for Cancer Research.